Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Intrepida Bio, a US-based immunotherapy developer exploiting research with University of Salerno origins, received $9.5m in equity funding from Sofinnova Investments and Canaan on Tuesday. The cash marks Intrepida’s first funding and will help develop antibodies targeting the cancer-causing BAG3 mechanism, as Intrepida aims for regulatory permission to move into the clinic. BAG3’s potential potency was discovered by Maria Caterina Turco, a professor of biochemistry at Salerno’s department of medicine, surgery and dentistry, whose findings led to the formation of…
